Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002)
Carboplatin plus nab-paclitaxel with atezolizumab is a potentially feasible treatment option for advanced nonsquamous NSCLC with renal impairment.
Authors
- Yoshimasa Shiraishi (ORCID: https://orcid.org/0000-0001-5015-193X)
- Junji Kishimoto (ORCID: https://orcid.org/0000-0002-3833-4052)
- Kosuke Kashiwabara (ORCID: https://orcid.org/0000-0003-3103-8055)
- Kohei Yoshimine
- Tadashi Sakaguchi (ORCID: https://orcid.org/0000-0003-1103-4276)
- Kazushige Wakuda (ORCID: https://orcid.org/0000-0002-6369-2388)
- Hidetoshi Hayashi (ORCID: https://orcid.org/0000-0001-8787-5587)
- Kazuto Furuyama
- Risa Ebina‐Shibuya (ORCID: https://orcid.org/0000-0001-9031-5070)
- Hirotaka Matsumoto (ORCID: https://orcid.org/0000-0003-4538-6456)
- Takayuki Shimose
- Yuri Taniguchi (ORCID: https://orcid.org/0000-0001-6409-1739)
- Shoichi Kuyama (ORCID: https://orcid.org/0000-0002-6079-3511)
- Isamu Okamoto (ORCID: https://orcid.org/0000-0002-7587-6096)
- Kazunori Tobino (ORCID: https://orcid.org/0000-0002-3456-6833)
- Yuichiro Kimura (ORCID: https://orcid.org/0000-0003-4091-2429)
- Yukihiro Toi (ORCID: https://orcid.org/0000-0001-5983-3531)
- Haruki Kobayashi
- Masahide Mori
- Ayano Mashimoto
Institutions
- Kyushu University (JP)
- Tohoku University (JP)
- Shizuoka Cancer Center (JP)
- Saiseikai Kumamoto Hospital (JP)
- Toneyama National Hospital (JP)
- Kyushu Hospital (JP)
- Japan Community Healthcare Organization (JP)
- Iwakuni Medical Center (JP)
- Hyogo Prefectural Amagasaki General Medical Center (JP)
- Yokohama Municipal Citizen's Hospital (JP)
- Aso Iizuka Hospital (JP)
- Saiseikai Fukuoka General Hospital (JP)
- Soka Municipal Hospital (JP)
- Kumamoto Medical Center (JP)
- Sendai Kousei Hospital (JP)
- Kindai University (JP)
Publication Details
- Journal
- Lung Cancer
- Published
- 2025-04-18
- DOI
- https://doi.org/10.1016/j.lungcan.2025.108543
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Medpace
- Taiho Pharmaceutical
- Novocure
- Boehringer Ingelheim Japan
- Sysmex Corporation
- Seagen
- Daiichi-Sankyo
- Eisai
- Astellas Pharma
- Shionogi
- Otsuka Pharmaceutical
- Ono Pharmaceutical
- Novartis Pharma
- Pfizer Japan
- Chugai Pharmaceutical
- Eli Lilly Japan
- Bayer Yakuhin
- Daiichi Sankyo Europe